EndoPredict ® in early hormone receptor-positive, HER2-negative breast cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/32436145/

EPclin led to a change in therapy recommendations in one third of the patients. Clinico-pathological parameters such as younger age, smaller tumor size, positive nodal status, intermediate histological grade and intermediate Ki-67 had a significant influence on the use of EndoPredict ® .